Key facts
- One-carbon Tx’s last known valuation is $11.4M (Dec 2024).
- It has raised $31.6M; the latest was Later Stage VC ($16.4M) in Dec 2025.
- Notable investors include Nordic Mentor Network For Entrepreneurship, EIT Health, Matwin, Vinnova.
- Status: Privately Held (backing).
- ·The complete investor list — 4 names
- ·Watchlist + deal alerts for One-carbon Tx
- ·The full record, as it builds
Funding rounds
No funding rounds for One-carbon Tx are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About One-carbon Tx
Developer of pre-clinical biotechnology intended to develop therapeutics utilizing synthetic lethality to target the DNA damage response (DDR) for treating cancer and inflammation. The company focuses on developing the poly adenosine diphosphate-ribose polymerase (PARP) inhibitor concept for treating Breast Cancer gene (BRCA) mutated cancer, enabling healthcare professionals to develop inhibitors that cause replication stress and the death of cancer cells.
- Sector
- Healthcare
- HQ
- Solna, Sweden
- Founded
- 2019
- Employees
- 5
- Website
- one-carbon.com/
- Ownership
- Privately Held (backing)
One-carbon Tx doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in One-carbon Tx shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on One-carbon Tx in its N-PORT filings yet. We sweep new filings monthly.